Investment analysts at StockNews.com began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) in a report issued on Thursday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
Separately, Cantor Fitzgerald increased their price target on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st.
Read Our Latest Stock Analysis on VNDA
Vanda Pharmaceuticals Stock Performance
Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) last issued its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. The company had revenue of $50.47 million for the quarter. As a group, research analysts forecast that Vanda Pharmaceuticals will post -0.49 EPS for the current year.
Institutional Trading of Vanda Pharmaceuticals
Hedge funds have recently made changes to their positions in the business. SageView Advisory Group LLC acquired a new stake in shares of Vanda Pharmaceuticals in the first quarter valued at approximately $34,000. Meeder Asset Management Inc. acquired a new stake in shares of Vanda Pharmaceuticals in the second quarter valued at approximately $39,000. ORG Wealth Partners LLC acquired a new stake in shares of Vanda Pharmaceuticals in the third quarter valued at approximately $40,000. SG Americas Securities LLC acquired a new stake in shares of Vanda Pharmaceuticals in the second quarter valued at approximately $61,000. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Vanda Pharmaceuticals by 18.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 2,425 shares during the last quarter. 88.14% of the stock is owned by institutional investors and hedge funds.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Featured Stories
- Five stocks we like better than Vanda Pharmaceuticals
- Energy and Oil Stocks Explained
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- The Basics of Support and Resistance
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Compound Interest and Why It Matters When Investing
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.